Clinical trial
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
NCT00110994 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00110994 |
|---|---|
| Title | Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma |
| Official title | Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma |
| Lead sponsor | Bayer, Industry |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Melanoma |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo, Dacarbazine |
| Enrollment | 101 |
| Start date | Apr 1, 2005 |
| Primary completion | Oct 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | May 17, 2005 |
| Last update posted | Jun 8, 2015 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: